• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Prime Medicine, Inc. - Common Stock (NQ:PRME)

    3.710 +0.040 (+1.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,312,576
    Open 3.700
    Bid (Size) 3.680 (2,100)
    Ask (Size) 3.750 (100)
    Prev. Close 3.670
    Today's Range 3.490 - 3.720
    52wk Range 2.670 - 6.940
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Prime Medicine to Participate in Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +5.1%
    +5.1%
    1 Month
    +24.5%
    +24.5%
    3 Month
    +6.9%
    +6.9%
    6 Month
    -5.6%
    -5.6%
    1 Year
    +11.1%
    +11.1%

    More News

    Read More
    News headline image
    Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine (NASDAQ:PRME) Q1 Results Show Revenue Miss and Narrower Loss as Key Pipeline Milestones Loom ↗
    Via Chartmill
    News headline image
    Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    News headline image
    Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine to Present at Jefferies Global Healthcare Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine to Participate in Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine to Present at Jefferies Global Healthcare Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Prime Medicine to Participate in Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
    Via TokenRing AI
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is Prime Medicine, Inc. - Common Stock publicly traded?
    Yes, Prime Medicine, Inc. - Common Stock is publicly traded.
    What exchange does Prime Medicine, Inc. - Common Stock trade on?
    Prime Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Prime Medicine, Inc. - Common Stock?
    The ticker symbol for Prime Medicine, Inc. - Common Stock is PRME on the Nasdaq Stock Market
    What is the current price of Prime Medicine, Inc. - Common Stock?
    The current price of Prime Medicine, Inc. - Common Stock is 3.710
    When was Prime Medicine, Inc. - Common Stock last traded?
    The last trade of Prime Medicine, Inc. - Common Stock was at 09/03/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.